<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01604642</url>
  </required_header>
  <id_info>
    <org_study_id>ACTICA</org_study_id>
    <nct_id>NCT01604642</nct_id>
  </id_info>
  <brief_title>Role of Activin A (ActA) in the Human Cancer Cachexia</brief_title>
  <official_title>Role of Activin A (ActA) in the Human Cancer Cachexia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the investigators study is to investigate the role of a hormone named Activin A&#xD;
      (ActA) in the development of the skeletal muscle atrophy caused by cancer. According to the&#xD;
      investigators hypothesis, ActA could be released by the tumor and activate a muscle atrophy&#xD;
      gene program. To answer this question, the investigators plan first to compare circulating&#xD;
      levels of ActA in cancer patients with and without cachexia. In a second step, the&#xD;
      investigators would like to assess whether ActA circulating levels are predictive for the&#xD;
      development of cachexia and short survival.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">January 1, 2016</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Circulating Activin A level</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dietary assessment measured by SNAQ score and 3-Day intake</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body mass index</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mid arm muscle circumference calculated by the triceps skinfold and the mid arm circumference</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition measured by bioimpedance</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle strength as measured by grip strength</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as assessed using the QLQ-C30</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>cachectic versus no cachectic patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>blood tests, muscular biopsies</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood tests and muscular biopsies</intervention_name>
    <description>blood tests and muscular biopsies</description>
    <arm_group_label>cachectic versus no cachectic patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-year-old or older&#xD;
&#xD;
          -  Colorectal or lung cancer demonstrated by histology or cytology&#xD;
&#xD;
          -  New diagnosis or new recurrence&#xD;
&#xD;
          -  Expected survival more than 3 months&#xD;
&#xD;
          -  No previous history of other cancer in the last 5 years&#xD;
&#xD;
          -  No pregnancy or lactation&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-caucasian&#xD;
&#xD;
          -  Major digestive malabsorption&#xD;
&#xD;
          -  Major depression&#xD;
&#xD;
          -  Artificial nutrition&#xD;
&#xD;
          -  Height doses of steroids (&gt;1 mg/kg hydrocortisone equivalent)&#xD;
&#xD;
          -  Hyperthyroidism&#xD;
&#xD;
          -  Other causes of malnutrition&#xD;
&#xD;
          -  Expected survival less than 3 months&#xD;
&#xD;
          -  Severely impaired walking&#xD;
&#xD;
          -  Anticoagulants or antiplatelet therapy&#xD;
&#xD;
          -  Disability or medical condition which might prevent the compliance to the protocol&#xD;
&#xD;
          -  Any conditions which may prevent the compliance to the protocol&#xD;
&#xD;
          -  Performance status ECOG &gt; ou = 4&#xD;
&#xD;
          -  Participation to other clinical studies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>May 4, 2012</study_first_submitted>
  <study_first_submitted_qc>May 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2012</study_first_posted>
  <last_update_submitted>March 29, 2018</last_update_submitted>
  <last_update_submitted_qc>March 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cachexia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

